AstraZeneca UK
This sponsor has funded 2 studies across 2 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 44035 | Ongoing | EU RMP category 3 | Post-authorisation active surveillance of the Safety of COVID-19 Vaccine AstraZeneca (AZD-1222) in the UK: A consortium study | No | No |
| 50803 | Planned | Not included in RMP | PredictIng the risk for first COPD severe exacerbation (PRECISE-X) | No | No |
PAS by Risk Management Plan (RMP) requirement
AstraZeneca UK
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
AstraZeneca UK
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
AstraZeneca UK
2 Study countries specified are the following:
- United Kingdom
- United Kingdom (Northern Ireland)